PEG-oligocholic acid telodendrimer micelles for the targeted delivery of doxorubicin to B-cell lymphoma

Journal of Controlled Release

Volumn 155, Issue 2, 2011, Pages 272-281

  Xiao, Kai ^a,b   Luo, Juntao ^a,c   Li, Yuanpei ^a   Lee, Joyce S ^a,d   Fung, Gabriel ^a   Lam, Kit S ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b SICHUAN UNIVERSITY   (China)

^c State University of New York Upstate Medical University: College of Medicine   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Biodistribution; Cancer therapy; Cardiotoxicity; Doxorubicin; Drug delivery; Nanotherapeutics; Polymeric micelles

Indexed keywords

BIODISTRIBUTIONS; CANCER THERAPY; CARDIOTOXICITY; DOXORUBICIN; NANOTHERAPEUTICS; POLYMERIC MICELLE;

DISEASES; DRUG DELIVERY; DRUG DOSAGE; ENZYMES; MAMMALS; ONCOLOGY; LOADING;

MICELLES;

CHOLIC ACID; CREATINE KINASE; DENDRIMER; DOXORUBICIN; LACTATE DEHYDROGENASE; MACROGOL; ASPARTATE AMINOTRANSFERASE; CARBOHYDRATE DERIVATIVE; OLIGOCHOLIC ACID; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; B CELL LYMPHOMA; CONFERENCE PAPER; CONTROLLED STUDY; CREATINE KINASE BLOOD LEVEL; CYTOTOXICITY; DRUG DELIVERY SYSTEM; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG FORMULATION; DRUG PENETRATION; DRUG STABILITY; DRUG TARGETING; FEMALE; IN VITRO STUDY; LACTATE DEHYDROGENASE BLOOD LEVEL; MAXIMUM TOLERATED DOSE; MICELLE; MICELLIZATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; RAJI CELL; SURVIVAL TIME; SUSTAINED DRUG RELEASE; T CELL LYMPHOMA; AREA UNDER THE CURVE; BODY WEIGHT; CELL PROLIFERATION; CELL VIABILITY; COMPETITIVE INHIBITION; DRUG ACCUMULATION; DRUG HALF LIFE; DRUG RETENTION; FLUORESCENCE MICROSCOPY; LYMPHOMA CELL; STRUCTURE ACTIVITY RELATION; TUMOR VOLUME;

ANIMALS; ANTIBIOTICS, ANTINEOPLASTIC; CELL LINE, TUMOR; CELL SURVIVAL; CHOLIC ACID; DENDRIMERS; DOSE-RESPONSE RELATIONSHIP, DRUG; DOXORUBICIN; DRUG CARRIERS; FEMALE; HUMANS; INJECTIONS, INTRAVENOUS; KAPLAN-MEIER ESTIMATE; LYMPHOMA, B-CELL; MICE; MICE, INBRED BALB C; MICELLES; MICROSCOPY, CONFOCAL; MICROSCOPY, FLUORESCENCE; PARTICLE SIZE; POLYETHYLENE GLYCOLS; SOLUBILITY; TISSUE DISTRIBUTION; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 80054115363     PISSN: 01683659     EISSN: 18734995     Source Type: Journal    
DOI: 10.1016/j.jconrel.2011.07.018     Document Type: Conference Paper

References (30)

1. J. Park, P.M. Fong, J. Lu, K.S. Russell, C.J. Booth, W.M. Saltzman, and T.M. Fahmy PEGylated PLGA nanoparticles for the improved delivery of doxorubicin Nanomedicine 5 4 2009 410 418
2. Y. Fukumori, and H. Ichikawa Nanoparticles for cancer therapy and diagnosis Adv. Powder Technol. 17 1 2006 1 28 (Pubitemid 43259046)
3. G. Sharma, S. Anabousi, C. Ehrhardt, and M.N.V.R. Kumar Liposomes as targeted drug delivery systems in the treatment of breast cancer J. Drug Target. 14 5 2006 301 310 (Pubitemid 44173296)
4. S. Kazakov, and K. Levon Liposome-nanogel structures for future pharmaceutical applications Curr. Pharm. Des. 12 36 2006 4713 4728 (Pubitemid 44835139)
5. E.R. Gillies, and J.M.J. Frechet Dendrimers and dendritic polymers in drug delivery Drug Discov. Today 10 1 2005 35 43 (Pubitemid 40164817)
6. A.N. Lukyanov, and V.P. Torchilin Micelles from lipid derivatives of water-soluble polymers as delivery systems for poorly soluble drugs Adv. Drug Deliv. Rev. 56 9 2004 1273 1289 (Pubitemid 38510474)
7. T.L. Andresen, S.S. Jensen, and K. Jorgensen Advanced strategies in liposomal cancer therapy: problems and prospects of active and tumor specific drug release Prog. Lipid Res. 44 1 2005 68 97 (Pubitemid 40313220)
8. B.F. El-Rayes, D. Ibrahim, A.F. Shields, P.M. LoRusso, M.M. Zalupski, and P.A. Philip Phase I study of liposomal doxorubicin (Doxil) and cyclophosphamide in solid tumors Invest. New Drugs 23 1 2005 57 62 (Pubitemid 39505951)
9. Y. Bae, N. Nishiyama, S. Fukushima, H. Koyama, M. Yasuhiro, and K. Kataoka Preparation and biological characterization of polymeric micelle drug carriers with intracellular pH-triggered drug release property: tumor permeability, controlled subcellular drug distribution, and enhanced in vivo antitumor efficacy Bioconjug. Chem. 16 1 2005 122 130 (Pubitemid 40129685)
10. Y. Tsukioka, Y. Matsumura, T. Hamaguchi, H. Koike, F. Moriyasu, and T. Kakizoe Pharmaceutical and biomedical differences between micellar doxorubicin (NK911) and liposomal doxorubicin (Doxil) Jpn. J. Cancer Res. 93 10 2002 1145 1153 (Pubitemid 35314960)
11. K. Xiao, J. Luo, W.L. Fowler, Y. Li, J.S. Lee, L. Xing, R.H. Cheng, L. Wang, and K.S. Lam A self-assembling nanoparticle for paclitaxel delivery in ovarian cancer Biomaterials 30 30 2009 6006 6016
12. Y. Li, K. Xiao, J. Luo, J. Lee, S. Pan, and K.S. Lam A novel size-tunable nanocarrier system for targeted anticancer drug delivery J. Control. Release 144 3 2010 314 323
13. J. Luo, K. Xiao, Y. Li, J.S. Lee, L. Shi, Y.H. Tan, L. Xing, R. Holland Cheng, G.Y. Liu, and K.S. Lam Well-defined, size-tunable, multifunctional micelles for efficient paclitaxel delivery for cancer treatment Bioconjug. Chem. 21 7 2010 1216 1224
14. K. Xiao, Y. Li, J. Luo, J.S. Lee, W. Xiao, A.M. Gonik, R.G. Agarwal, and K.S. Lam The effect of surface charge on in vivo biodistribution of PEG-oligocholic acid based micellar nanoparticles Biomaterials 32 13 2011 3435 3446
15. Y. Li, K. Xiao, J. Luo, W. Xiao, J.S. Lee, A.M. Gonik, J. Kato, T.A. Dong, and K.S. Lam Well-defined, reversible disulfide cross-linked micelles for on-demand paclitaxel delivery Biomaterials 32 27 2011 6633 6645
16. S. Kim, Y. Shi, J.Y. Kim, K. Park, and J.X. Cheng Overcoming the barriers in micellar drug delivery: loading efficiency, in vivo stability, and micelle-cell interaction Expert Opin Drug Deliv 7 1 2010 49 62
17. K. Letchford, R. Liggins, and H. Burt Solubilization of hydrophobic drugs by methoxy poly(ethylene glycol)-block-polycaprolactone diblock copolymer micelles: theoretical and experimental data and correlations J. Pharm. Sci. 97 3 2008 1179 1190
18. Y.Z. Du, Q. Weng, H. Yuan, and F.Q. Hu Synthesis and antitumor activity of stearate-g-dextran micelles for intracellular doxorubicin delivery ACS Nano 4 11 2010 6894 6902
19. X. Shuai, H. Ai, N. Nasongkla, S. Kim, and J. Gao Micellar carriers based on block copolymers of poly(epsilon-caprolactone) and poly(ethylene glycol) for doxorubicin delivery J. Control. Release 98 3 2004 415 426 (Pubitemid 39093952)
20. B.L. Lum, M.P. Gosland, S. Kaubisch, and B.I. Sikic Molecular targets in oncology: implications of the multidrug resistance gene Pharmacotherapy 13 2 1993 88 109 (Pubitemid 23103055)
21. F. Wang, Y.C. Wang, S. Dou, M.H. Xiong, T.M. Sun, and J. Wang Doxorubicin-tethered responsive gold nanoparticles facilitate intracellular drug delivery for overcoming multidrug resistance in cancer cells ACS Nano 5 5 2011 3679 3692
22. F.Q. Hu, L.N. Liu, Y.Z. Du, and H. Yuan Synthesis and antitumor activity of doxorubicin conjugated stearic acid-g-chitosan oligosaccharide polymeric micelles Biomaterials 30 36 2009 6955 6963
23. M.J. Shieh, C.Y. Hsu, L.Y. Huang, H.Y. Chen, F.H. Huang, and P.S. Lai Reversal of doxorubicin-resistance by multifunctional nanoparticles in MCF-7/ADR cells J. Control. Release 152 3 2011 418 425
24. F.M. Kievit, F.Y. Wang, C. Fang, H. Mok, K. Wang, J.R. Silber, R.G. Ellenbogen, and M. Zhang Doxorubicin loaded iron oxide nanoparticles overcome multidrug resistance in cancer in vitro J. Control. Release 152 1 2011 76 83
25. K. Breistol, H.R. Hendriks, and O. Fodstad Superior therapeutic efficacy of N-L-leucyl-doxorubicin versus doxorubicin in human melanoma xenografts correlates with higher tumour concentrations of free drug Eur. J. Cancer 35 7 1999 1143 1149 (Pubitemid 29339200)
26. E. Boven, H.M. Schluper, C.A. Erkelens, and H.M. Pinedo Doxorubicin compared with related compounds in a nude mouse model for human ovarian cancer Eur. J. Cancer 26 9 1990 983 986
27. A.A. Gabizon Pegylated liposomal doxorubicin: metamorphosis of an old drug into a new form of chemotherapy Cancer Investig. 19 4 2001 424 436 (Pubitemid 32525189)
28. D.M. Vail, L.D. Kravis, A.J. Cooley, R. Chun, and E.G. MacEwen Preclinical trial of doxorubicin entrapped in sterically stabilized liposomes in dogs with spontaneously arising malignant tumors Cancer Chemother. Pharmacol. 39 5 1997 410 416 (Pubitemid 27078125)
29. L. Peng, R. Liu, J. Marik, X. Wang, Y. Takada, and K.S. Lam Combinatorial chemistry identifies high-affinity peptidomimetics against alpha4beta1 integrin for in vivo tumor imaging Nat. Chem. Biol. 2 7 2006 381 389 (Pubitemid 43936939)
30. K. Xiao, J. Luo, Y. Li, W. Xiao, J.S. Lee, A.M. Gonik, and K.S. Lam The passive targeting of polymeric micelles in various types and sizes of tumor models Nanosci. Nanotechnol. Lett. 2 2 2010 79 85